Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Stock Information for Coya Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.